Efficacy of perioperative gabapentin use in patients with idiopathic scoliosis undergoing fusion surgery: a systematic review and meta-analysis.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bas, Jose Luis
  • Bonilla, Fernando
  • Perez, Silvia
  • Rubio-Belmar, Pedro Antonio

Grupos

Abstract

PURPOSE: This study aimed to assess whether the perioperative use of gabapentin was associated with decreased opioid use. METHODS: A meta-analysis was performed using PubMed, Embase, Scopus, and Cochrane Library. The randomized clinical trials included were focused on patients with adolescent idiopathic scoliosis who underwent posterior fusion surgery and were treated with gabapentin versus placebo medicine. The primary outcomes were opioid consumption at 24, 48, 72, and 96 h; time to introduction of oral medication, length of hospital stay, and period of urinary catheterization were also recorded. Data were combined using the Review Manager 5.4 software. RESULTS: Four randomized clinical trials with a pool of 196 adolescent patients (mean age: 14.8 ± 2.0 years) were included. At 24 and 48 h after surgery, opioid consumption was significantly lower in the gabapentin group: (standardized mean difference [SMD]: -0.50; 95% confidence interval [CI] - 0.79 to - 0.22) and (SMD: - 0.59; 95% CI - 0.88 to - 0.30), respectively. At 72 and 96 h, there were no significant differences between studies: (SMD: - 0.19; 95% CI - 0.52 to 0.13) and (SMD: 0.12; 95% CI - 0.25 to 0.50), respectively. Regarding the administration type, there were significant differences in favor of the 15 mg/kg subgroup with 600 mg at 48 h (SMD: - 0.69; 95% CI - 1.08 to - 0.30). There were no significant differences concerning the time to introduction of oral medication (MD: - 0.08; 95% CI - 0.39 to 0.23), hospitalization time (MD: - 0.12; 95% CI - 0.40 to 0.16), or period of urinary catheterization (SMD: - 0.27; 95% CI - 0.58 to 0.05). CONCLUSIONS: Gabapentin decreased opioid consumption during the first 48 h. Doses of 15 mg/kg showed superiority in reducing opioid consumption in the first 48 h. LEVEL OF EVIDENCE I: Diagnostic: individual cross-sectional studies with consistently applied reference standard and blinding.

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Datos de la publicación

ISSN/ISSNe:
0940-6719, 1432-0932

EUROPEAN SPINE JOURNAL  SPRINGER

Tipo:
Article
Páginas:
2521-2532
Factor de Impacto:
1,231 SCImago
Cuartil:
Q1 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Adolescent idiopathic scoliosis; Gabapentin; Meta-analysis; Multimodal pain control; Opioid consumption

Proyectos asociados

EFECTIVIDAD BIOMECÁNICA DE LOS TORNILLOS TRANSDISCALES EN LA ESPONDILOLISTESIS L5-S1 FRENTE A TORNILLOS TRANSPEDICULARES Y CAJAS.

Investigador Principal: ISABEL COLLADOS MAESTRE

2014_0666_CRC_COLLADOS . 2014

ESTUDIO DE FASE IIB, ALEATORIZADO, DOBLE CIEGO, CONTROLADO MEDIANTE PLACEBO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LA VACUNA DE 4 ANTÍGENOS DE STAPHYLOCOCCUS AUREUS (SA4AG) EN ADULTOS QUE VAN A SOMETERSE A INTERVENCIONES QUIRÚRGICAS PROGRAMADAS DE ARTRODESIS VERTEBRAL POSTERIOR (LUMBAR) INSTRUMENTADA.

Investigador Principal: JUAN BAUTISTA MOLLAR MASERES

B3451002 . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2015

BEMIPARINA (HEPARINA DE BAJO PESO MOLECULAR) EN LA PREVENCION DE LA ENFERMEDAD TROMBOEMBOLICA TRAS CIRUGIA DE SUSTITUCION DE TOTAL DE RODILLA. ESTUDIO FASE III ALEATORIO, CONTROLADO, SECUENCIAL, DOBLE CIEGO, PARA COMPARAR LA EFICACIA Y SEGURIDAD DE BEMIPARINA (3.500 U.I. ANTI-XA) CON ENOXAPARINA (40 MG.)

Investigador Principal: PALOMA BAS HERMIDA

ROVI-III/3

ENSAYO CLINICO PARA ESTUDIOS SUCESIVOS DE EFICACIA Y SEGURIDAD DE CELECOXIB: ESTUDIO MULTICENTRICO, DOBLE CIEGO, ALEATORIZADO, DE GRUPOS PARALELOS PARA COMPARAR LA EFICACIA Y TOLERABILIDAD DE CELECOXIB FRENTE A IBUPROFENO EN ESGUINCES DE TOBILLO (SUCCESS-IIE)

Investigador Principal: PALOMA BAS HERMIDA

I49-00-12-155

ESTUDIO DE PRUEBA DE CONCEPTO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DEL ELEZANUMAB EN LA LESIÓN AGUDA TRAUMÁTICA DE MÉDULA ESPINAL CERVICAL.

Investigador Principal: TERESA BAS HERMIDA

M16-077 . 2020

Cirugía de corrección de deformidad vertebral en pacientes con AME tratados con Spinraza.

Investigador Principal: MIGUEL DE PEDRO ABASCAL

SPINAME . 2022

Cita

Compartir